Two-year evaluation in advanced lung cancers at Allegheny Health Network demonstrated improved access to optimal treatment while reducing healthcare costs SAN DIEGO , Sept. 21, 2020 /PRNewswire/ -- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to
SAN DIEGO , June 22, 2020 /PRNewswire/ -- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, announces the availability of 10,000
Further expands Company's patent portfolio in pursuit of worldwide intellectual property protection for Primer-Switch technology for the field of oncology SAN DIEGO , Sept. 23, 2020 /PRNewswire/ -- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to
Biocept's patented Target Selector™ test for identification of TRK proteins enables physicians to rapidly and cost-effectively identify the potential presence of NTRK fusions used to inform on treatment options SAN DIEGO , Nov. 21, 2019 /PRNewswire/ -- Biocept, Inc.
SAN DIEGO --(BUSINESS WIRE)--Jul. 13, 2023-- Biocept, Inc . (Nasdaq: BIOC) (“Biocept” or the “Company”) announces that M. Faye Wilson , Board Chair, passed away unexpectedly on Monday, July 10 . The Board of Directors and staff of Biocept extend their deepest condolences to the Wilson family and
Biocept's patented Target Selector™ technology enables new specimen type--cerebrospinal fluid (CSF)--to identify biomarkers that can aid physicians in making treatment decisions SAN DIEGO , Jan. 14, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy
SAN DIEGO , Feb. 14, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the promotion of Cory J.
SAN DIEGO , Oct. 27, 2016 /PRNewswire/ -- Biocept, Inc. ( NASDAQ : BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable information to physicians to improve cancer treatment, announces the appointment of David